GLIA Diagnostics (H10x)
The first portable, accurate brain injury diagnostic device.
Glia Diagnostics (GLIA) was formed for the sole purpose of developing a diagnostic specific for Traumatic Brain Injury (TBI) with emphasis on mild TBI (mTBI/concussion).
The US based inventors isolated a group of biomarkers (micro RNA (miRNA)), which showed enormous potential not only for diagnosis (acute), but also the greater advantage of a prognostic (chronic) treatment monitoring tool, to maximise optimal Return to Activity (RTA) decision making.
GLIA is now advancing the ‘marriage’ of the biomarkers to a Point of Care (POC) companion device, able to define TBI within 20 minutes using a fingerstick blood sample.
Achievements:
Five clinical studies.
Point of Care (POC) platform able to detect TBI in 20 mins.
Patents for biomarkers and PCT published for POC.
Edmond Sorich, Director/Founder